Oman Pharmaceuticals and Healthcare Report Q1 2013
Business Monitor International, February 2013, Pages: 85
BMI View
Oman’s commendable public healthcare system and high-class tertiary and quaternary care hospitals will increase the uptake of medical tourism by GCC citizens. The Omani pharmaceutical market will continue to remain heavily reliant on imports due to the costly need to source raw ingredients for local manufacturing and lack of R&D backing. However, despite the strict drug pricing system, we are likely to see more multinational companies penetrating the market and expanding volume sales, by addressing the increasing burden of non-communicable diseases in the country.
Headline Expenditure Projections
- Pharmaceuticals: OMR151mn (US$391mn) in 2011 to OMR166mn in 2012; +9.9% in local currency terms and +11.3% in US dollar terms. Forecast revised upwards due to modifications to historical figures.
- Healthcare: OMR742mn (US$1.93bn) in 2011 to OMR839mn (US$2.21bn) in 2012; +13.1% in local currency terms and +14.6% in US dollar terms. Forecast revised upwards due to modifications to historical figures.
- Medical devices: OMR40mn (US$105mn) in 2011 to OMR44mn (US$116mn) in 2012; +9.5%
in local currency terms and +10.9% in US dollar terms. Forecast revised upwards due to modifications to historical figures.
Executive Summary 5
SWOT Analysis 7
Oman Pharmaceuticals And Healthcare Industry SWOT 7
Oman Political SWOT 8
Oman Economic SWOT 8
Oman Business Environment SWOT 9
Pharmaceutical Risk/Reward Ratings 10
Table: Middle East And Africa (MEA) Pharmaceutical Risk/Reward Ratings, Q113 10
Rewards 12
Risks 13
Oman - Market Summary 15
Regulatory Regime 17
Regulatory Developments 18
Intellectual Property Regime 18
Table: IP Laws In Oman 19
Regional Harmonisation 19
Pricing And Reimbursement Regime 20
Recent Pricing And Reimbursement Developments 21
Free Trade Agreements 22
Industry Developments 24
Epidemiology 24
Communicable Diseases 25
Non-Communicable Diseases 26
Public Health Developments 27
Healthcare Sector 28
Table: Number Of Health Centres In Oman By Region 28
Table: Number And Type Of Health Institutions In Oman 29
Healthcare System Developments 29
Table: Healthcare Reform Targets 31
Private Healthcare Sector 31
Private Healthcare Developments 32
Healthcare Funding 33
Healthcare Insurance 33
Telemedicine 34
Medical Tourism 34
Research And Biotechnology 36
Clinical Trials 37
Medical Devices 38
Industry Forecast Scenario 39
Overall Market Forecast 39
Table: Oman Pharmaceutical Sales, Historical Data And Forecasts, 2007-2017 40
Key Growth Factors - Industry 41
Table: Oman Healthcare Expenditure Trends, Historical Data and Forecasts 42
Table: Oman Government Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017 42
Table: Oman Private Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017 43
Key Growth Factors - Macroeconomic 44
Table: Oman - GDP By Expenditure, Current Prices Breakdown, 2008-2016 48
Prescription Drug Market Forecast 49
Table: Oman Prescription Drug Market Indicators, Historical Data And Forecasts, 2009-2017 50
Patented Drug Market Forecast 51
Table: Oman Patented Drug Market Indicators, Historical Data and Forecasts 52
Generic Drug Market Forecast 53
Table: Oman Generics Drug Market Indicators, Historical Data And Forecasts, 2009-2017 54
OTC Medicine Market Forecast 55
Table: Oman Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts, 2009-2017 56
Pharmaceutical Trade Forecast 57
Table: Oman Pharmaceutical Trade Data And Forecasts (US$mn), 2009-2017 58
Table: Oman Pharmaceutical Trade Data And Forecasts (OMRmn), 2009-2017 58
Medical Device Market Forecast 59
Table: Oman Medical Device Market Indicators, Historical Data and Forecasts, 2009-2017 60
Other Healthcare Data Forecasts 61
Key Risks To BMI's Forecasts 62
Competitive Landscape 63
Pharmaceutical Sector 63
Domestic Industry 63
Foreign Industry 64
Pharmaceutical Distribution 65
Company Profiles 66
Local Companies 66
Zynova/Oman Pharmaceutical Products Company (OPPC) 66
National Pharmaceutical Industries (NPI) 68
Multinational Companies 70
Novartis 70
GlaxoSmithKline 72
Sanofi 73
Johnson & Johnson 74
Demographic Outlook 75
Table: Population By Age Group, 1990-2020 ('000) 76
Table: Population By Age Group, 1990-2020 (% of total) 76
Table: Key Population Ratios, 1990-2020 77
Table: Rural/Urban Population Split, 1990-2020 77
Glossary 79
BMI Methodology 81
How We Generate Our Pharmaceutical Industry Forecasts 81
Risk/Reward Ratings Methodology 82
Ratings Overview 82
Table: Pharmaceutical Business Environment Indicators 83
Weighting 84
Table: Weighting Of Components 84
Sources 84
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
